InsiderTrades.com logo
Eric Bjerkholt net worth and biography
  • Phone
  • Email
  • Website

Eric Bjerkholt Biography and Net Worth

CFO of Mirum Pharmaceuticals

Eric Bjerkholt joined Mirum as chief financial officer in September 2023. Eric joined Mirum from Chinook Therapeutics, Inc. where served as chief financial officer overseeing financial reporting, planning and budgeting, internal controls, investor relations, facilities, and information technology functions. Prior to Chinook, he served as CFO at Aimmune Therapeutics, Inc. Before Aimmune, Eric worked at Sunesis Pharmaceuticals, Inc., IntraBiotics Pharmaceuticals, Inc., LifeSpring Nutrition, Inc., and Age Wave, LLC. Prior to joining industry, Eric spent nearly a decade in healthcare investment banking at J.P. Morgan & Company, Inc. He is currently a member of the board of directors of CalciMedica, Inc., Cerus Corporation and Surrozen, Inc.

Eric holds an MBA from Harvard Business School and a Cand.Oecon degree from the University of Oslo in Norway.

What is Eric Bjerkholt's net worth?

The estimated net worth of Eric Bjerkholt is at least $7.50 million as of December 12th, 2024. Mr. Bjerkholt owns 162,133 shares of Mirum Pharmaceuticals stock worth more than $7,503,515 as of March 27th. This net worth approximation does not reflect any other assets that Mr. Bjerkholt may own. Additionally, Mr. Bjerkholt receives an annual salary of $600,400.00 as CFO at Mirum Pharmaceuticals. Learn More about Eric Bjerkholt's net worth.

How old is Eric Bjerkholt?

Mr. Bjerkholt is currently 64 years old. There are 5 older executives and no younger executives at Mirum Pharmaceuticals. Learn More on Eric Bjerkholt's age.

What is Eric Bjerkholt's salary?

As the CFO of Mirum Pharmaceuticals, Inc., Mr. Bjerkholt earns $600,400.00 per year. There are 4 executives that earn more than Mr. Bjerkholt. The highest earning executive at Mirum Pharmaceuticals is Mr. Christopher Peetz, Co-Founder, CEO and Director, who commands a salary of $1,310,000.00 per year. Learn More on Eric Bjerkholt's salary.

How do I contact Eric Bjerkholt?

The corporate mailing address for Mr. Bjerkholt and other Mirum Pharmaceuticals executives is 950 TOWER LANE SUITE 1050, FOSTER CITY CA, 94404. Mirum Pharmaceuticals can also be reached via phone at (650) 667-4085 and via email at ir@mirumpharma.com. Learn More on Eric Bjerkholt's contact information.

Has Eric Bjerkholt been buying or selling shares of Mirum Pharmaceuticals?

Eric Bjerkholt has not been actively trading shares of Mirum Pharmaceuticals during the past quarter. Most recently, on Wednesday, March 27th, Eric Bjerkholt bought 2,000 shares of Mirum Pharmaceuticals stock. The stock was acquired at an average cost of $24.80 per share, with a total value of $49,600.00. Following the completion of the transaction, the chief financial officer now directly owns 14,000 shares of the company's stock, valued at $347,200. Learn More on Eric Bjerkholt's trading history.

Who are Mirum Pharmaceuticals' active insiders?

Mirum Pharmaceuticals' insider roster includes Eric Bjerkholt (CFO), Ian Clements (CFO), James Flynn (Major Shareholder), Michael Grey (Chairman of the Board), Patrick Heron (Director), Jolanda Howe (SVP), Lara Longpre (Chief Development Officer), Christopher Peetz (Co-Founder, CEO and Director), Joanne Quan (Chief Medical Officer), Peter Radovich (President & Chief Operating Officer), Saira Ramasastry (Director), and Pamela Vig (Insider). Learn More on Mirum Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Mirum Pharmaceuticals?

During the last twelve months, Mirum Pharmaceuticals insiders bought shares 4 times. They purchased a total of 3,680 shares worth more than $124,300.35. During the last twelve months, insiders at the sold shares 17 times. They sold a total of 172,113 shares worth more than $7,304,987.14. The most recent insider tranaction occured on March, 17th when SVP Jolanda Howe sold 57,606 shares worth more than $2,554,826.10. Insiders at Mirum Pharmaceuticals own 22.9% of the company. Learn More about insider trades at Mirum Pharmaceuticals.

Information on this page was last updated on 3/17/2025.

Eric Bjerkholt Insider Trading History at Mirum Pharmaceuticals

See Full Table

Eric Bjerkholt Buying and Selling Activity at Mirum Pharmaceuticals

This chart shows Eric Bjerkholt's buying and selling at Mirum Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$200k$0$200kTotal Insider BuyingTotal Insider Selling

Mirum Pharmaceuticals Company Overview

Mirum Pharmaceuticals logo
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.
Read More

Today's Range

Now: $46.28
Low: $45.83
High: $47.20

50 Day Range

MA: $48.02
Low: $43.01
High: $53.16

2 Week Range

Now: $46.28
Low: $23.14
High: $54.23

Volume

393,047 shs

Average Volume

509,454 shs

Market Capitalization

$2.27 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.04